Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Other Operating Expenses (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Other Operating Expenses for 2 consecutive years, with -$492827.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$492827.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.0 million, a N/A change, with the full-year FY2020 number at $1.9 million, changed N/A from a year prior.
  • Other Operating Expenses was -$492827.0 for Q3 2025 at Inhibikase Therapeutics, down from -$358420.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of -$358420.0 in Q2 2025 to a low of -$1.2 million in Q1 2025.